Mahakpreet Singh, Ruchika Sharma and Anoop Kumar* Pages 87 - 93 ( 7 )
Background: Recently, Food and Drug Administration (FDA) has approved sodium/ glucose co-transporter 2 (SGLT2) inhibitors for the treatment of diabetes mellitus. However, regarding adverse drug reactions (ADRs) of SGLT2 inhibitors in large group of population, very less information is available. Thus, we have tried to find out the risk profile of SGLT2 inhibitors.
Materials and Methods: A total of 1,042 studies have been published from Nov. 2012-Nov. 2017 regarding SGLT2 inhibitors. After inclusion and exclusion criteria, 27 studies have been selected for the analysis of risk.
Results and Discussion: The emerging evidence indicates various adverse drug reactions such as foot and toe amputation, cancer, diabetic ketoacidosis, bone fracture risk and urinary as well as mycotic genital infection. The causality assessment has shown a correlation between SGLT2 inhibitors and diabetic ketoacidosis and urinary tract infection.
Conclusion: In conclusion, Marketing Authorization Holder (MAH) and Regulatory Authorities (RA) should monitor various adverse drug reactions such as diabetic ketoacidosis and urinary tract infection with the use of SGLT2 inhibitor.
SGLT2 inhibitors, risks, diabetes mellitus, ADRs, metabolic disorders, anti-diabetic drugs.
Department of Pharmacy Practice, Indo-Soviet Friendship Pharmacy College (ISFCP), Moga, Punjab, Department of Biotechnology, Indo-Soviet Friendship Institute of Professional Studies (ISFIPS), Moga, Punjab, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPERRaebareli), Lucknow, UP